Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × elotuzumab × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 48 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1

Conditions

Multiple Myeloma 1 Lymphoma 1

Interventions

Rituximab 1153 Cyclophosphamide 1099 Vincristine 553 Doxorubicin 495 Etoposide 445 Prednisone 419 Cytarabine 401 fludarabine 394 Methotrexate 358 Dexamethasone 338 fludarabine phosphate 324 Lenalidomide 295 Filgrastim 294 Bendamustine Hydrochloride 230 Radiotherapy 229 venetoclax 217 ibrutinib 205 obinutuzumab 193 Melphalan 190 Peripheral Blood Stem Cell Transplantation 189 Granulocyte Colony-Stimulating Factor 172 Gemcitabine 168 Bortezomib 164 Busulfan 156 Whole-Body Irradiation 154 Mycophenolic Acid 144 Tacrolimus 124 Specimen Handling 121 Calcium Dobesilate 121 pegaspargase 120

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡